Prana Biotechnology, today announced that it has secured funding of A$7 million through a placement of approximately 35.9 million fully paid ordinary shares at a price of A$0.195 per share (equivalent to approximately US$2.03 per Nasdaq listed ADR).
Author: Alterity Therapeutics
Prana Biotechnology today reported on the progress of its lead development asset PBT2 in Phase II trials for Huntington disease and Alzheimer’s disease. Across the two trials approximately 37% have been dosed to 6 months or longer, twice the duration of the previous Phase II Alzheimer’s trial . 1,2 PBT2 has been well tolerated and both trials are on schedule with very pleasing retention rates and compliance. Each Independent Data Safety Monitoring Board for the two trials met at the end of March and recommended that each trial continue as planned without any protocol changes.
Prana Biotechnology today reported that it has received a A$2.5 million cash refund under the R&D Tax Incentive Program, a program administered by AusIndustry and the Australian Taxation Office. This payment is part of approximately $5.8 million expected to be received for the 2011-12 and 2012-13 financial years.
Prana Biotechnology is pleased to advise that its Share Purchase Plan (SPP) closed on Friday 26 April 2013 at 5.00 pm (EST) with applications received for 10,370,488 ordinary shares (New Shares).
Prana Biotechnology has unveiled a world first, patient-reported outcomes study for Huntington’s Disease (HD) in a poster presentation at the 17th Annual Congress of Parkinson’s Disease and Movement Disorders being held in Sydney this week.
Prana Biotechnology today welcomed the release of data which indicates its drug candidate PBT434 shows significant disease-modifying capability in multiple animal models of Parkinson’s Disease (PD) with potential utility in a range of movement disorders.
Prana Biotechnology today announced that it has received approval from the Austin Health Human Research Ethics Committee (HREC) to commence a 12-month open label extension study with Alzheimer’s Disease patients participating in Prana’s IMAGINE trial.
Professor Rudy Tanzi has been appointed as Chief Scientific Advisor to the Company. Professor Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University, and Director of the Genetics and Aging Research Unit at Massachusetts General Hospital (MGH). Professor Tanzi has been investigating the genetics of neurological disease since 1980 when he participated in the study that led to the first disease gene being identified by genetic analysis (Huntington's Disease).